Loading clinical trials...
Loading clinical trials...
A Phase I Open-Label Study of LNP3794 (BI3011441) in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
Conditions
Interventions
LNP3794
Locations
4
Belgium
Cliniques universitaires Saint-Luc
Brussels, Belgium
Amsterdam UMC
Amsterdam, Netherlands
Sarah Cannon Research Institute
London, United Kingdom
The Christie NHS Foundation
Manchester, United Kingdom
Start Date
September 22, 2020
Primary Completion Date
February 23, 2022
Completion Date
June 30, 2022
Last Updated
March 17, 2023
Lead Sponsor
Lupin Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions